Pipeline

Biocytogen is committed to developing innovative antibody drugs that meet the needs of patients, focusing on oncology, autoimmune, inflammatory, metabolic and and other diseases. Taking full advantage of its unique advantage in innovative drug development, the company now has more than 10 R & D pipelines including monoclonal antibodies, bispecific antibodies, ADC drugs and so on. Our pipeline is supported by a strong clinical development team and abundant clinical resources.

To learn more about our pipeline, please contact BD-[email protected].

Candidate

Target

Combination

Indication

Phase

Upcoming Milestone

Rights

News/Press Release



Clinical-stage Drug Candidates
 


YH003



CD40



PD-1 Melanoma Global MRCT

Phase II

2022 Q4 Complete Recruitment Global Biocytogen/Eucure Biopharma Announce First Patient Dosed in Phase II Clinical Trial of YH003 Combination Therapy as a First-Line Treatment for Mucosal Melanoma



PD-1 Pancreatic
cancer
Global MRCT

Phase II

2022 Q4 Complete  Recruitment
Monotherapy
Solid tumors China  Phase I 2022 Q2 Patient
Recruitment
PD-1+
YH001
Solid tumors Australia

IND

2023 Q1 Complete Recruitment
PD-1 Mucosal  melanoma China 2022 Q3 Complete Recruitment
YH001


CTLA-4


PD-1 Non-small-cell
lung cancer
(NSCLC)
Global MRCT

Phase II

2023 Q1 Patient
Recruitment
Global


Biocytogen/Eucure Biopharma to Present Clinical Data from YH003 (anti-CD40 mAb) and YH001 (anti-CTLA-4 mAb) Trials at 2022 American Society of Clinical Oncology (ASCO) Annual Meeting


PD-1 Hepatocellular
carcinoma
(HCC)
Global MRCT

Phase II

 

2023 Q1 Patient
Recruitment
Monotherapy Solid tumors China 

Phase I

2022 Q2  Complete Site Visit
PD-L1 Sarcoma  Global MRCT 2022 Q3 Patient
Recruitment
YH002


OX40


Monotherapy  Solid Tumors Australia

Phase 1

2022 Q3
Complete Phase I
trial
Global First Patient Dosing for a Phase I Multi-regional Clinical Trial of YH002 (Anti-OX40 mAb) in Combination with YH001 (Anti-CTLA-4 mAb) in Australia
Monotherapy Solid Tumors China/USA

Phase 1

Launch based on
clinical results in
Australia
YH001 Solid Tumors China/Australia

Phase I

2023 Q1 Complete Recruitment
YH004

4-1BB

PD-1 Hematological
malignancies
Australia

Phase 1

2023 Q4 Complete Recruitment Global
PD-1 Solid tumors Australia/China

Phase 1

 

2023 Q4 Complete Recruitment
YH005-ADC Claudin18.2-
ADC
Solid tumors Australia

IND -> Phase 1

Remegen
Developmental -stage Drug Candidates
 
 
 
YH008 PD-1/CD40
(bispecific
antibody)
  Solid tumors CMC Global 
YH006 CTLA-4/
OX40
(bispecific
antibody)
  Solid Tumors CMC   Global    
YH009 RSV   Prevention/
Treatment for
RSV infection 
CMC Global 
YH010 PD-L1/IL-12   Solid Tumors Discovery   Global    
YH011 PD-L1/
cytokine
  Solid Tumors Discovery   GeneQuantum Healthcare  
YH012 Bispecific
antibody
ADC
  Solid tumors Discovery   Global   
YH013 Bispecific
antibody
ADC
Solid tumors Discovery Global 

 

Back to top